Duran G - Search Results

1

Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy.

Duran G, Cruz R, Aguín S, Barros F, Giráldez JM, Bernárdez B, Zarra I, López-López R, Carracedo Á, Lamas MJ. Duran G, et al. Cancer Chemother Pharmacol. 2021 Nov;88(5):813-823. doi: 10.1007/s00280-021-04330-1. Epub 2021 Jul 26. Cancer Chemother Pharmacol. 2021. PMID: 34309735

2

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.

Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A, Barros F. Lamas MJ, et al. Among authors: duran g. Cancer Chemother Pharmacol. 2012 Jun;69(6):1591-9. doi: 10.1007/s00280-012-1866-2. Epub 2012 Apr 26. Cancer Chemother Pharmacol. 2012. PMID: 22535333

3

Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.

Duran G, Aguín S, Cruz R, Barros F, Giráldez JM, Bernárdez B, López-López R, Carracedo Á, Lamas MJ. Duran G, et al. Head Neck. 2019 Aug;41(8):2704-2715. doi: 10.1002/hed.25754. Epub 2019 Apr 11. Head Neck. 2019. PMID: 30973677

4

Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.

Balboa E, Duran G, Lamas MJ, Gomez-Caamaño A, Celeiro-Muñoz C, Lopez R, Carracedo A, Barros F. Balboa E, et al. Among authors: duran g. Pharmacogenomics. 2010 Jun;11(6):747-61. doi: 10.2217/pgs.10.51. Pharmacogenomics. 2010. PMID: 20504250 Clinical Trial.

5

X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.

Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B, Rana-Diez P, Lopez R, Carracedo A, Barros F. Lamas MJ, et al. Among authors: duran g. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):138-44. doi: 10.1016/j.ijrobp.2010.09.053. Epub 2010 Dec 16. Int J Radiat Oncol Biol Phys. 2012. PMID: 21167658

6

Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.

Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F. Lamas MJ, et al. Among authors: duran g. Pharmacogenomics. 2011 Mar;12(3):433-42. doi: 10.2217/pgs.10.196. Pharmacogenomics. 2011. PMID: 21449681

7

Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.

Balboa-Beltrán E, Duran G, Lamas MJ, Carracedo A, Barros F. Balboa-Beltrán E, et al. Among authors: duran g. Mayo Clin Proc. 2015 Sep;90(9):1298-303. doi: 10.1016/j.mayocp.2015.05.005. Epub 2015 Jul 22. Mayo Clin Proc. 2015. PMID: 26210704

8

Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

Duran G, Cruz R, Simoes AR, Barros F, Giráldez JM, Bernárdez B, Anido U, Candamio S, López-López R, Carracedo Á, Lamas MJ. Duran G, et al. J Chemother. 2020 Oct;32(6):310-322. doi: 10.1080/1120009X.2020.1764281. Epub 2020 May 22. J Chemother. 2020. PMID: 32441565

9

Anti-EGFR therapy in first-line colorectal cancer.

Lamas MJ, Duran G, Gallardo E. Lamas MJ, et al. Among authors: duran g. Expert Rev Anticancer Ther. 2011 Oct;11(10):1499-503. doi: 10.1586/era.11.149. Expert Rev Anticancer Ther. 2011. PMID: 21999123

10

Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.

Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A; EPICOLON Consortium. Fernandez-Rozadilla C, et al. Among authors: duran g. Pharmacogenomics J. 2013 Jun;13(3):209-17. doi: 10.1038/tpj.2012.2. Epub 2012 Feb 7. Pharmacogenomics J. 2013. PMID: 22310351

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page